Projects per year
The chemotherapeutic Parthenolide is an exciting new candidate for the treatment of acute lymphoblastic leukemia, but like many other small-molecule drugs, it has low aqueous solubility. As a consequence, Parthenolide can only be administered clinically in the presence of harmful cosolvents. Accordingly, we describe the synthesis, characterization, and testing of a range of biocompatible triblock copolymer micelles as particle-based delivery vectors for the hydrophobic drug Parthenolide. The drug-loaded particles are produced via an emulsion-to-micelle transition method, and the effects of introducing anionic and cationic surface charges on stability, drug sequestration, biocompatibility, and efficacy are investigated. Significantly, we demonstrate high levels of efficacy in the organic solvent-free systems against human mesenchymal stem cells and primary T-acute lymphoblastic leukemia patient cells, highlighting the effectiveness of the delivery vectors for the treatment of acute lymphoblastic leukemia.
- Bristol BioDesign Institute
- acute lymphoblastic leukemia (ALL)
- Synthetic biology
FingerprintDive into the research topics of 'Functionalized triblock copolymer vectors for the treatment of acute lymphoblastic leukemia'. Together they form a unique fingerprint.
- 3 Finished
Supercharged enzyme-polymer surfactant bioblocks for the preparation of organophosphate decontaminating materials
1/05/16 → 21/12/19
1/12/13 → 1/12/16